首页 > 最新文献

American journal of clinical pathology最新文献

英文 中文
Artificial intelligence-based algorithms for the diagnosis of prostate cancer: A systematic review. 基于人工智能的前列腺癌诊断算法:系统综述。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-06-03 DOI: 10.1093/ajcp/aqad182
Stefano Marletta, Albino Eccher, Filippo Maria Martelli, Nicola Santonicco, Ilaria Girolami, Aldo Scarpa, Fabio Pagni, Vincenzo L'Imperio, Liron Pantanowitz, Stefano Gobbo, Davide Seminati, Angelo Paolo Dei Tos, Anil Parwani

Objectives: The high incidence of prostate cancer causes prostatic samples to significantly affect pathology laboratories workflow and turnaround times (TATs). Whole-slide imaging (WSI) and artificial intelligence (AI) have both gained approval for primary diagnosis in prostate pathology, providing physicians with novel tools for their daily routine.

Methods: A systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was carried out in electronic databases to gather the available evidence on the application of AI-based algorithms to prostate cancer.

Results: Of 6290 articles, 80 were included, mostly (59%) dealing with biopsy specimens. Glass slides were digitized to WSI in most studies (89%), roughly two-thirds of which (66%) exploited convolutional neural networks for computational analysis. The algorithms achieved good to excellent results about cancer detection and grading, along with significantly reduced TATs. Furthermore, several studies showed a relevant correlation between AI-identified histologic features and prognostic predictive variables such as biochemical recurrence, extraprostatic extension, perineural invasion, and disease-free survival.

Conclusions: The published evidence suggests that AI can be reliably used for prostate cancer detection and grading, assisting pathologists in the time-consuming screening of slides. Further technologic improvement would help widening AI's adoption in prostate pathology, as well as expanding its prognostic predictive potential.

目的:前列腺癌的高发病率导致前列腺样本对病理实验室的工作流程和周转时间(TAT)产生了重大影响。整体滑动成像(WSI)和人工智能(AI)已被批准用于前列腺病理的初步诊断,为医生的日常工作提供了新的工具:根据《系统综述和元分析首选报告项目》指南,在电子数据库中开展了一项系统综述,以收集将基于人工智能的算法应用于前列腺癌的现有证据:在 6290 篇文章中,有 80 篇被收录,其中大部分(59%)涉及活检标本。大多数研究(89%)将玻璃切片数字化为 WSI,其中约三分之二(66%)利用卷积神经网络进行计算分析。这些算法在癌症检测和分级方面取得了良好到卓越的结果,同时大大缩短了 TAT。此外,一些研究表明,人工智能识别的组织学特征与预后预测变量(如生化复发、前列腺外扩展、会阴侵袭和无病生存期)之间存在相关性:已发表的证据表明,人工智能可以可靠地用于前列腺癌的检测和分级,帮助病理学家完成耗时的切片筛选工作。进一步的技术改进将有助于扩大人工智能在前列腺病理学中的应用,并扩大其预后预测潜力。
{"title":"Artificial intelligence-based algorithms for the diagnosis of prostate cancer: A systematic review.","authors":"Stefano Marletta, Albino Eccher, Filippo Maria Martelli, Nicola Santonicco, Ilaria Girolami, Aldo Scarpa, Fabio Pagni, Vincenzo L'Imperio, Liron Pantanowitz, Stefano Gobbo, Davide Seminati, Angelo Paolo Dei Tos, Anil Parwani","doi":"10.1093/ajcp/aqad182","DOIUrl":"10.1093/ajcp/aqad182","url":null,"abstract":"<p><strong>Objectives: </strong>The high incidence of prostate cancer causes prostatic samples to significantly affect pathology laboratories workflow and turnaround times (TATs). Whole-slide imaging (WSI) and artificial intelligence (AI) have both gained approval for primary diagnosis in prostate pathology, providing physicians with novel tools for their daily routine.</p><p><strong>Methods: </strong>A systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was carried out in electronic databases to gather the available evidence on the application of AI-based algorithms to prostate cancer.</p><p><strong>Results: </strong>Of 6290 articles, 80 were included, mostly (59%) dealing with biopsy specimens. Glass slides were digitized to WSI in most studies (89%), roughly two-thirds of which (66%) exploited convolutional neural networks for computational analysis. The algorithms achieved good to excellent results about cancer detection and grading, along with significantly reduced TATs. Furthermore, several studies showed a relevant correlation between AI-identified histologic features and prognostic predictive variables such as biochemical recurrence, extraprostatic extension, perineural invasion, and disease-free survival.</p><p><strong>Conclusions: </strong>The published evidence suggests that AI can be reliably used for prostate cancer detection and grading, assisting pathologists in the time-consuming screening of slides. Further technologic improvement would help widening AI's adoption in prostate pathology, as well as expanding its prognostic predictive potential.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139929561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterizing the role of informal payments in the delivery of pathology and clinical laboratory services. 描述非正规支付在提供病理学和临床实验室服务中的作用。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-06-03 DOI: 10.1093/ajcp/aqad188
Emily H Glynn, Timothy Amukele, Olusegun Soge, Geoffrey Baird, Taryn Vian

Objectives: Informal payments (IPs) are unofficial cash or in-kind payments for goods or services that should be covered by the health care system. They are a common but regressive method of financing health care in low- and lower-middle-income countries (LMICs). This study aims to characterize the prevalence and impact of IPs on pathology and laboratory medicine (PALM) services.

Methods: From September 2021 to September 2022, PALM staff were surveyed about the frequency, determinants, and impacts of IPs in their respective workplaces.

Results: In total, 268 responses were received, and 46.6% (125/268) reported experience with IPs. These 125 participants were more likely to work in the public sector and in LMICs. Approximately 65% reported accepting IPs to perform tests or release results. Obtaining faster results was the most commonly perceived reason for patients offering IPs. Overall, participants reported that IPs had more negative than positive impacts on their workplace.

Conclusions: This represents a first step in characterizing IPs within PALM and how this practice may affect access to these services in LMICs. Specifically, the fact that faster turnaround time was the most frequently perceived reason for offering IPs uncovers a potential barrier to improving PALM capacity in these regions.

目标:非正规支付(IPs)是指以非官方的现金或实物支付本应由医疗保健系统提供的商品或服务。在低收入和中低收入国家(LMICs),非正规支付是一种常见的医疗融资方式,但却存在倒退现象。本研究旨在描述 IPs 对病理学和实验室医学(PALM)服务的普遍性和影响:方法:从 2021 年 9 月至 2022 年 9 月,对病理和实验室医学(PALM)工作人员进行调查,了解 IPs 在他们各自工作场所的发生频率、决定因素和影响:结果:共收到 268 份回复,46.6%(125/268)的回复者表示有过 IPs 的经历。这 125 名参与者更有可能在公共部门和低收入和中等收入国家工作。约 65% 的参与者表示接受 IP 进行检测或发布结果。获得更快的结果是患者提供 IP 的最常见原因。总体而言,参与者认为知识产权对其工作场所的负面影响多于正面影响:这标志着我们迈出了第一步,了解了 PALM 中 IP 的特点,以及这种做法会如何影响低收入和中等收入国家获得这些服务。具体而言,更快的周转时间是提供 IPs 的最常见原因,这一事实揭示了提高这些地区 PALM 能力的潜在障碍。
{"title":"Characterizing the role of informal payments in the delivery of pathology and clinical laboratory services.","authors":"Emily H Glynn, Timothy Amukele, Olusegun Soge, Geoffrey Baird, Taryn Vian","doi":"10.1093/ajcp/aqad188","DOIUrl":"10.1093/ajcp/aqad188","url":null,"abstract":"<p><strong>Objectives: </strong>Informal payments (IPs) are unofficial cash or in-kind payments for goods or services that should be covered by the health care system. They are a common but regressive method of financing health care in low- and lower-middle-income countries (LMICs). This study aims to characterize the prevalence and impact of IPs on pathology and laboratory medicine (PALM) services.</p><p><strong>Methods: </strong>From September 2021 to September 2022, PALM staff were surveyed about the frequency, determinants, and impacts of IPs in their respective workplaces.</p><p><strong>Results: </strong>In total, 268 responses were received, and 46.6% (125/268) reported experience with IPs. These 125 participants were more likely to work in the public sector and in LMICs. Approximately 65% reported accepting IPs to perform tests or release results. Obtaining faster results was the most commonly perceived reason for patients offering IPs. Overall, participants reported that IPs had more negative than positive impacts on their workplace.</p><p><strong>Conclusions: </strong>This represents a first step in characterizing IPs within PALM and how this practice may affect access to these services in LMICs. Specifically, the fact that faster turnaround time was the most frequently perceived reason for offering IPs uncovers a potential barrier to improving PALM capacity in these regions.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139721200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AmpFire HPV and ScreenFire RS HPV validation trial. AmpFire HPV 和 ScreenFire RS HPV 验证试验。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-06-03 DOI: 10.1093/ajcp/aqad181
Jun Hou, Jerome L Belinson, Hui Du, Changzhong Li, Wei Zhang, Lijie Zhang, Yi Zhang, Xinfeng Qu, Ruifang Wu

Objectives: The human papillomavirus (HPV) screening assays from Atila Biosystems, including the new AmpFire (14 type) and ScreenFire RS (13 type), were subjected to a series of validation tests.

Methods: We used a set of samples from the Chinese Multi-Site Screening Trial (previously tested with cobas 4800 and the next-generation SeqHPV) to satisfy Meijer's criteria for clinical end-point validation. We selected 556 self-collected specimens composed of 273 high-risk HPV (hrHPV) positives and 283 hrHPV negatives on the cobas 4800 and SeqHPV. Of the 273 hrHPV-positive cases, 108 had a disease end point of cervical intraepithelial neoplasia grade 2 (CIN2) or higher, including 47 with cervical intraepithelial neoplasia grade 3 (CIN3+) or higher. We simulated the VALGENT framework for inter- and intralaboratory validation and evaluated the new 4-channel risk-stratified ScreenFire assay in a hierarchal fashion.

Results: Both AmpFire and ScreenFire detected 106 (98.1%) of 108 cases with CIN2 or higher, with specificities of 56.7% and 58.1%, respectively. Intralaboratory concordance for 2 runs of AmpFire and ScreenFire was 95.13% and 96.03%, respectively, for overall hrHPV types and 99.10% and 99.46%, respectively, for HPV 16. The interlaboratory concordance of AmpFire and ScreenFire was 93.68% and 94.04% for overall hrHPV and 98.92% and 99.28%, respectively, for HPV 16. Other genotype correlation percentages were similarly high, with κs ranging from 0.86 to 0.94. The ScreenFire RS assay demonstrated excellent "genotype-specific concordance" when evaluated for "clinical guidance" in a hierarchal fashion (noting only the highest risk channel) with both the cobas 4800 and SeqHPV for less than CIN2, CIN2, and CIN3 or higher.

Conclusions: The excellent intra- and interlaboratory reproducibility and the established clinical performance, together with the platforms' simplicity, make these assays particularly applicable to low-resource settings.

目的:对阿蒂拉生物系统公司生产的人类乳头瘤病毒(HPV)筛查试剂盒(包括新型AmpFire(14型)和ScreenFire RS(13型))进行一系列验证试验:我们使用了一组来自中国多点筛查试验的样本(之前使用 cobas 4800 和新一代 SeqHPV 进行过测试),以满足 Meijer 的临床终点验证标准。我们选择了 556 份自取标本,其中包括 273 份经 cobas 4800 和 SeqHPV 检测的高危人乳头瘤病毒 (hrHPV) 阳性标本和 283 份 hrHPV 阴性标本。在 273 例 hrHPV 阳性病例中,108 例的疾病终点为宫颈上皮内瘤变 2 级(CIN2)或以上,其中 47 例为宫颈上皮内瘤变 3 级(CIN3+)或以上。我们模拟了用于实验室间和实验室内验证的 VALGENT 框架,并对新型 4 通道风险分级 ScreenFire 检测进行了分级评估:结果:AmpFire 和 ScreenFire 检测出 108 例 CIN2 或以上病例中的 106 例(98.1%),特异性分别为 56.7% 和 58.1%。两次 AmpFire 和 ScreenFire 检测的实验室间一致性分别为:hrHPV 全部类型为 95.13% 和 96.03%,HPV 16 为 99.10% 和 99.46%。对于整体 hrHPV,AmpFire 和 ScreenFire 的实验室间一致性分别为 93.68% 和 94.04%,对于 HPV 16,分别为 98.92% 和 99.28%。其他基因型的相关性也同样很高,κs 在 0.86 到 0.94 之间。ScreenFire RS 检测与 cobas 4800 和 SeqHPV 对 CIN2 以下、CIN2 和 CIN3 或更高的 "临床指导 "进行分级评估时(只注意最高风险通道),表现出极好的 "基因型特异性一致性":实验室内和实验室间极好的重现性、成熟的临床表现以及平台的简易性使这些检测方法特别适用于资源匮乏的环境。
{"title":"AmpFire HPV and ScreenFire RS HPV validation trial.","authors":"Jun Hou, Jerome L Belinson, Hui Du, Changzhong Li, Wei Zhang, Lijie Zhang, Yi Zhang, Xinfeng Qu, Ruifang Wu","doi":"10.1093/ajcp/aqad181","DOIUrl":"10.1093/ajcp/aqad181","url":null,"abstract":"<p><strong>Objectives: </strong>The human papillomavirus (HPV) screening assays from Atila Biosystems, including the new AmpFire (14 type) and ScreenFire RS (13 type), were subjected to a series of validation tests.</p><p><strong>Methods: </strong>We used a set of samples from the Chinese Multi-Site Screening Trial (previously tested with cobas 4800 and the next-generation SeqHPV) to satisfy Meijer's criteria for clinical end-point validation. We selected 556 self-collected specimens composed of 273 high-risk HPV (hrHPV) positives and 283 hrHPV negatives on the cobas 4800 and SeqHPV. Of the 273 hrHPV-positive cases, 108 had a disease end point of cervical intraepithelial neoplasia grade 2 (CIN2) or higher, including 47 with cervical intraepithelial neoplasia grade 3 (CIN3+) or higher. We simulated the VALGENT framework for inter- and intralaboratory validation and evaluated the new 4-channel risk-stratified ScreenFire assay in a hierarchal fashion.</p><p><strong>Results: </strong>Both AmpFire and ScreenFire detected 106 (98.1%) of 108 cases with CIN2 or higher, with specificities of 56.7% and 58.1%, respectively. Intralaboratory concordance for 2 runs of AmpFire and ScreenFire was 95.13% and 96.03%, respectively, for overall hrHPV types and 99.10% and 99.46%, respectively, for HPV 16. The interlaboratory concordance of AmpFire and ScreenFire was 93.68% and 94.04% for overall hrHPV and 98.92% and 99.28%, respectively, for HPV 16. Other genotype correlation percentages were similarly high, with κs ranging from 0.86 to 0.94. The ScreenFire RS assay demonstrated excellent \"genotype-specific concordance\" when evaluated for \"clinical guidance\" in a hierarchal fashion (noting only the highest risk channel) with both the cobas 4800 and SeqHPV for less than CIN2, CIN2, and CIN3 or higher.</p><p><strong>Conclusions: </strong>The excellent intra- and interlaboratory reproducibility and the established clinical performance, together with the platforms' simplicity, make these assays particularly applicable to low-resource settings.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139745810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of multidisciplinary team meeting histopathology review and its impact on revised reports: Analysis of a national quality improvement program. 多学科小组会议组织病理学审查的作用及其对修订报告的影响:国家质量改进计划分析。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-06-03 DOI: 10.1093/ajcp/aqad183
Eoghan O'Connor, Ann Treacy, Aine Mitchell, Niall Swan

Objectives: We conducted the first Irish national study assessing the value of multidisciplinary team meeting review in pathology practice and its impact on error detection before treatment.

Methods: Public and private pathology laboratories across Ireland capture their quality activities using standardized codes and submit their data to a centralized database (National Quality Assurance Intelligence System) overseen by the National Histopathology Quality Improvement (NHQI) program. A total of 1,437,746 histopathology and cytopathology cases submitted to the NHQI program over a 60-month period (January 2017 to December 2021) were included in this study. Cases were analyzed with respect to multidisciplinary team meeting peer review and the presence of a revised report (amended or corrected report), a surrogate marker for error detection before treatment.

Results: Across all cases assessed, 13.74% (197,587) underwent multidisciplinary team meeting discussion. Cases discussed at review had a statistically significantly higher rate of revised reports (1.25% [2470]) than cases not discussed at review (0.16% [1959]) (Pearson χ2, 6619.26; P < .0001; odds ratio, 8.00 [95% CI, 7.54-8.49]). Overall, multidisciplinary team meeting review made it 8 times more likely to detect an error before treatment. Cancer resections had the highest rate of review at 55.29% (46,806), reflecting the prioritization of oncology case discussion at review meetings.

Conclusions: The multidisciplinary team meeting review process plays a valuable role in pathology error detection. A pathologist's participation in the review process comes with a clinically significant workload that needs to be recognized for future workforce planning. This study highlighted the positive role pathologists play in enhancing patient safety.

目的:我们进行了爱尔兰首次全国性研究,评估多学科团队会议审查在病理学实践中的价值及其对治疗前错误检测的影响:我们开展了爱尔兰首次全国性研究,评估多学科团队会议审查在病理实践中的价值及其对治疗前错误检测的影响:方法:爱尔兰的公立和私立病理实验室使用标准化代码记录其质量活动,并将数据提交至由国家组织病理学质量改进计划(NHQI)监督的中央数据库(国家质量保证情报系统)。本研究纳入了60个月内(2017年1月至2021年12月)提交给NHQI计划的共计143746例组织病理学和细胞病理学病例。研究分析了病例的多学科团队会议同行评审情况和修订报告(修订或更正报告)的存在情况,修订报告是治疗前发现错误的替代标志:在所有接受评估的病例中,13.74%(197587 例)的病例经过了多学科小组会议讨论。经复核讨论的病例修订报告率(1.25% [2470])明显高于未经复核讨论的病例(0.16% [1959]),差异有统计学意义(Pearson χ2,6619.26;P 结论:多学科团队会议复核是一种有效的方法:多学科团队会议审查流程在病理错误检测中发挥着重要作用。病理学家在参与审查过程的同时也承担着重要的临床工作量,这一点需要在未来的劳动力规划中得到认可。本研究强调了病理学家在提高患者安全方面发挥的积极作用。
{"title":"The role of multidisciplinary team meeting histopathology review and its impact on revised reports: Analysis of a national quality improvement program.","authors":"Eoghan O'Connor, Ann Treacy, Aine Mitchell, Niall Swan","doi":"10.1093/ajcp/aqad183","DOIUrl":"10.1093/ajcp/aqad183","url":null,"abstract":"<p><strong>Objectives: </strong>We conducted the first Irish national study assessing the value of multidisciplinary team meeting review in pathology practice and its impact on error detection before treatment.</p><p><strong>Methods: </strong>Public and private pathology laboratories across Ireland capture their quality activities using standardized codes and submit their data to a centralized database (National Quality Assurance Intelligence System) overseen by the National Histopathology Quality Improvement (NHQI) program. A total of 1,437,746 histopathology and cytopathology cases submitted to the NHQI program over a 60-month period (January 2017 to December 2021) were included in this study. Cases were analyzed with respect to multidisciplinary team meeting peer review and the presence of a revised report (amended or corrected report), a surrogate marker for error detection before treatment.</p><p><strong>Results: </strong>Across all cases assessed, 13.74% (197,587) underwent multidisciplinary team meeting discussion. Cases discussed at review had a statistically significantly higher rate of revised reports (1.25% [2470]) than cases not discussed at review (0.16% [1959]) (Pearson χ2, 6619.26; P < .0001; odds ratio, 8.00 [95% CI, 7.54-8.49]). Overall, multidisciplinary team meeting review made it 8 times more likely to detect an error before treatment. Cancer resections had the highest rate of review at 55.29% (46,806), reflecting the prioritization of oncology case discussion at review meetings.</p><p><strong>Conclusions: </strong>The multidisciplinary team meeting review process plays a valuable role in pathology error detection. A pathologist's participation in the review process comes with a clinically significant workload that needs to be recognized for future workforce planning. This study highlighted the positive role pathologists play in enhancing patient safety.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139705786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring the performance of an artificial intelligence-based robot that classifies blood tubes and performs quality control in terms of preanalytical errors: A preliminary study. 测量基于人工智能的机器人在分析前误差方面对血管进行分类和质量控制的性能:初步研究。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-06-03 DOI: 10.1093/ajcp/aqad179
Ali Rıza Şişman, Banu İşbilen Başok, İnanç Karakoyun, Ayfer Çolak, Uğur Bilge, Ferhat Demirci, Nuri Başoglu

Objectives: Artificial intelligence-based robotic systems are increasingly used in medical laboratories. This study aimed to test the performance of KANKA (Labenko), a stand-alone, artificial intelligence-based robot that performs sorting and preanalytical quality control of blood tubes.

Methods: KANKA is designed to perform preanalytical quality control with respect to error control and preanalytical sorting of blood tubes. To detect sorting errors and preanalytical inappropriateness within the routine work of the laboratory, a total of 1000 blood tubes were presented to the KANKA robot in 7 scenarios. These scenarios encompassed various days and runs, with 5 repetitions each, resulting in a total of 5000 instances of sorting and detection of preanalytical errors. As the gold standard, 2 experts working in the same laboratory identified and recorded the correct sorting and preanalytical errors. The success rate of KANKA was calculated for both the accurate tubes and those tubes with inappropriate identification.

Results: KANKA achieved an overall accuracy rate of 99.98% and 100% in detecting tubes with preanalytical errors. It was found that KANKA can perform the control and sorting of 311 blood tubes per hour in terms of preanalytical errors.

Conclusions: KANKA categorizes and records problem-free tubes according to laboratory subunits while identifying and classifying tubes with preanalytical inappropriateness into the correct error sections. As a blood acceptance and tube sorting system, KANKA has the potential to save labor and enhance the quality of the preanalytical process.

目的:基于人工智能的机器人系统越来越多地应用于医学实验室。本研究旨在测试 KANKA(Labenko)的性能,这是一种基于人工智能的独立机器人,可对血管进行分拣和分析前质量控制:KANKA 设计用于执行分析前质量控制,包括血管的错误控制和分析前分拣。为了检测实验室日常工作中的分拣错误和分析前的不适当性,KANKA 机器人在 7 个场景中总共检测了 1000 支血管。这些场景包括不同的日期和运行,每个场景重复 5 次,总共产生了 5000 个分类和分析前错误检测实例。作为金标准,在同一实验室工作的两名专家识别并记录了正确的分类和分析前错误。对准确的试管和识别错误的试管都计算了 KANKA 的成功率:结果:KANKA 的总体准确率为 99.98%,对分析前错误试管的检测率为 100%。在分析前错误方面,KANKA 每小时可对 311 支血管进行控制和分类:结论:KANKA 根据实验室子单元对无问题的试管进行分类和记录,同时识别分析前不适当的试管并将其分类到正确的错误区域。作为血液接收和试管分类系统,KANKA 有可能节省人力并提高分析前流程的质量。
{"title":"Measuring the performance of an artificial intelligence-based robot that classifies blood tubes and performs quality control in terms of preanalytical errors: A preliminary study.","authors":"Ali Rıza Şişman, Banu İşbilen Başok, İnanç Karakoyun, Ayfer Çolak, Uğur Bilge, Ferhat Demirci, Nuri Başoglu","doi":"10.1093/ajcp/aqad179","DOIUrl":"10.1093/ajcp/aqad179","url":null,"abstract":"<p><strong>Objectives: </strong>Artificial intelligence-based robotic systems are increasingly used in medical laboratories. This study aimed to test the performance of KANKA (Labenko), a stand-alone, artificial intelligence-based robot that performs sorting and preanalytical quality control of blood tubes.</p><p><strong>Methods: </strong>KANKA is designed to perform preanalytical quality control with respect to error control and preanalytical sorting of blood tubes. To detect sorting errors and preanalytical inappropriateness within the routine work of the laboratory, a total of 1000 blood tubes were presented to the KANKA robot in 7 scenarios. These scenarios encompassed various days and runs, with 5 repetitions each, resulting in a total of 5000 instances of sorting and detection of preanalytical errors. As the gold standard, 2 experts working in the same laboratory identified and recorded the correct sorting and preanalytical errors. The success rate of KANKA was calculated for both the accurate tubes and those tubes with inappropriate identification.</p><p><strong>Results: </strong>KANKA achieved an overall accuracy rate of 99.98% and 100% in detecting tubes with preanalytical errors. It was found that KANKA can perform the control and sorting of 311 blood tubes per hour in terms of preanalytical errors.</p><p><strong>Conclusions: </strong>KANKA categorizes and records problem-free tubes according to laboratory subunits while identifying and classifying tubes with preanalytical inappropriateness into the correct error sections. As a blood acceptance and tube sorting system, KANKA has the potential to save labor and enhance the quality of the preanalytical process.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139569400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Banff scoring of kidney allograft biopsies: "Manual" application vs software-assisted sign-out. 肾移植活检的 Banff 评分:"手动 "应用与软件辅助签出。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-06-03 DOI: 10.1093/ajcp/aqad180
Anthony J Demetris, Andrew J Lesniak, Benjamin A Popp, Ronald J Frencho, Marta I Minervini, Michael A Nalesnik, Mohamed I El Hag, Sundaram Hariharan, Parmjeet S Randhawa

Objectives: Pathologists interpreting kidney allograft biopsies using the Banff system usually start by recording component scores (eg, i, t, cg) using histopathologic criteria committed to memory. Component scores are then melded into diagnoses using the same manual/mental processes. This approach to complex Banff rules during routine sign-out produces a lack of fidelity and needs improvement.

Methods: We constructed a web-based "smart template" (software-assisted sign-out) system that uniquely starts with upstream Banff-defined additional diagnostic parameters (eg, infection) and histopathologic criteria (eg, percent interstitial inflammation) collectively referred to as feeder data that is then translated into component scores and integrated into final diagnoses using software-encoded decision trees.

Results: Software-assisted sign-out enables pathologists to (1) accurately and uniformly apply Banff rules, thereby eliminating human inconsistencies (present in 25% of the cohort); (2) document areas of improvement; (3) show improved correlation with function; (4) examine t-Distributed Stochastic Neighbor Embedding clustering for diagnosis stratification; and (5) ready upstream incorporation of artificial intelligence-assisted scoring of biopsies.

Conclusions: Compared with the legacy approach, software-assisted sign-out improves Banff accuracy and fidelity, more closely correlates with kidney function, is practical for routine clinical work and translational research studies, facilitates downstream integration with nonpathology data, and readies biopsy scoring for artificial intelligence algorithms.

目的:病理学家在使用班夫系统解读肾脏异体活组织切片时,通常首先使用记忆中的组织病理学标准记录成分分数(如 i、t、cg)。然后使用相同的手动/心算过程将成分分数合并为诊断结果。这种在常规签出过程中使用复杂班夫规则的方法缺乏真实性,需要改进:方法:我们构建了一个基于网络的 "智能模板"(软件辅助签出)系统,该系统从上游班夫定义的附加诊断参数(如感染)和组织病理学标准(如间质性炎症百分比)开始,这些参数和标准统称为馈线数据,然后通过软件编码的决策树将这些数据转化为成分分数并整合到最终诊断中:软件辅助签出使病理学家能够:(1) 准确统一地应用班夫规则,从而消除人为的不一致性(25% 的队列中存在这种情况);(2) 记录需要改进的领域;(3) 显示与功能的相关性得到改善;(4) 检查用于诊断分层的 t 分布随机邻接嵌入聚类;(5) 准备在上游纳入人工智能辅助活检评分:结论:与传统方法相比,软件辅助签出提高了 Banff 的准确性和保真度,与肾功能的相关性更强,对常规临床工作和转化研究非常实用,便于与非病理数据进行下游整合,并为人工智能算法的活检评分做好了准备。
{"title":"Banff scoring of kidney allograft biopsies: \"Manual\" application vs software-assisted sign-out.","authors":"Anthony J Demetris, Andrew J Lesniak, Benjamin A Popp, Ronald J Frencho, Marta I Minervini, Michael A Nalesnik, Mohamed I El Hag, Sundaram Hariharan, Parmjeet S Randhawa","doi":"10.1093/ajcp/aqad180","DOIUrl":"10.1093/ajcp/aqad180","url":null,"abstract":"<p><strong>Objectives: </strong>Pathologists interpreting kidney allograft biopsies using the Banff system usually start by recording component scores (eg, i, t, cg) using histopathologic criteria committed to memory. Component scores are then melded into diagnoses using the same manual/mental processes. This approach to complex Banff rules during routine sign-out produces a lack of fidelity and needs improvement.</p><p><strong>Methods: </strong>We constructed a web-based \"smart template\" (software-assisted sign-out) system that uniquely starts with upstream Banff-defined additional diagnostic parameters (eg, infection) and histopathologic criteria (eg, percent interstitial inflammation) collectively referred to as feeder data that is then translated into component scores and integrated into final diagnoses using software-encoded decision trees.</p><p><strong>Results: </strong>Software-assisted sign-out enables pathologists to (1) accurately and uniformly apply Banff rules, thereby eliminating human inconsistencies (present in 25% of the cohort); (2) document areas of improvement; (3) show improved correlation with function; (4) examine t-Distributed Stochastic Neighbor Embedding clustering for diagnosis stratification; and (5) ready upstream incorporation of artificial intelligence-assisted scoring of biopsies.</p><p><strong>Conclusions: </strong>Compared with the legacy approach, software-assisted sign-out improves Banff accuracy and fidelity, more closely correlates with kidney function, is practical for routine clinical work and translational research studies, facilitates downstream integration with nonpathology data, and readies biopsy scoring for artificial intelligence algorithms.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139715728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical validation of the Ion Torrent Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer as a stand-alone assay for single-nucleotide variants, insertions/deletions, and fusion genes: Challenges, performance, and perspectives. Ion Torrent Oncomine骨髓测定GX v2在Genexus集成测序仪上作为单核苷酸变异、插入/缺失和融合基因的独立测定的临床验证:挑战、性能和前景。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1093/ajcp/aqae063
Kritika Krishnamurthy, Jiani Chai, Xiaowei Liu, Yanhua Wang, Rizwan Naeem, D Yitzchak Goldstein

Objectives: Myeloid neoplasms require comprehensive characterization of genetic abnormalities, including single-nucleotide variants, small insertions and deletions, and fusions and translocations for management. The Oncomine Myeloid Assay GX v2 (Thermo Fisher Scientific) analyzes 17 full genes, 28 hotspot genes, 30 fusion driver genes, and 5 expression genes.

Methods: The validation set included 192 DNA samples, 28 RNA samples, and 9 cell lines and contrived controls. The DNA and RNA were extracted from both peripheral blood and bone marrow. Library preparation, templating, and sequencing was performed on the fully automated Genexus Integrated Sequencer (Thermo Fisher Scientific). The sequencing data were analyzed by manual curation, default Oncomine filters and the Oncomine Reporter (Thermo Fisher Scientific).

Results: Of the 600 reference pathogenic DNA variants targeted by the assay, concordance was seen in 98.3% of unfiltered variant call format files. Precision and reproducibility were 100%, and the lower limit of detection was 2% variant allele frequency for DNA. Inability to detect variants in long homopolymer regions intrinsic to the Ion Torrent chemistry led to 7 missed variants; 100% concordance was seen with reference RNA samples.

Conclusions: This extensive clinical validation of the Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer with its built-in bioinformatics pipeline and Ion Torrent Oncomine Reporter shows robust performance in terms of variant calling accuracy, precision, and reproducibility, with the advantage of a rapid turnaround time of 2 days. The greatest limitation is the inability to detect variants in long homopolymer regions.

目的:髓样肿瘤需要对基因异常进行全面鉴定,包括单核苷酸变异、小的插入和缺失、融合和易位,以便进行治疗。Oncomine 髓样检测 GX v2(赛默飞世尔科技公司)可分析 17 个全基因、28 个热点基因、30 个融合驱动基因和 5 个表达基因:验证集包括 192 份 DNA 样本、28 份 RNA 样本、9 个细胞系和假对照。DNA 和 RNA 均从外周血和骨髓中提取。文库制备、模板制作和测序均在全自动 Genexus Integrated Sequencer(赛默飞世尔科技公司)上进行。测序数据通过人工整理、默认 Oncomine 过滤器和 Oncomine Reporter(赛默飞世尔科技公司)进行分析:结果:在测定所针对的 600 个参考致病 DNA 变异中,98.3% 的未过滤变异调用格式文件具有一致性。精确度和再现性均为 100%,DNA 变异等位基因频率的检测下限为 2%。Ion Torrent化学方法无法检测长均聚物区域的变异,导致7个变异漏检;与参考RNA样本的一致性为100%:Oncomine Myeloid Assay GX v2在Genexus集成测序仪上进行了广泛的临床验证,该测序仪内置生物信息学管道和Ion Torrent Oncomine Reporter,在变异调用的准确性、精确性和可重复性方面表现出色,并具有2天快速反应的优势。最大的局限是无法检测长均聚物区域的变异。
{"title":"Clinical validation of the Ion Torrent Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer as a stand-alone assay for single-nucleotide variants, insertions/deletions, and fusion genes: Challenges, performance, and perspectives.","authors":"Kritika Krishnamurthy, Jiani Chai, Xiaowei Liu, Yanhua Wang, Rizwan Naeem, D Yitzchak Goldstein","doi":"10.1093/ajcp/aqae063","DOIUrl":"https://doi.org/10.1093/ajcp/aqae063","url":null,"abstract":"<p><strong>Objectives: </strong>Myeloid neoplasms require comprehensive characterization of genetic abnormalities, including single-nucleotide variants, small insertions and deletions, and fusions and translocations for management. The Oncomine Myeloid Assay GX v2 (Thermo Fisher Scientific) analyzes 17 full genes, 28 hotspot genes, 30 fusion driver genes, and 5 expression genes.</p><p><strong>Methods: </strong>The validation set included 192 DNA samples, 28 RNA samples, and 9 cell lines and contrived controls. The DNA and RNA were extracted from both peripheral blood and bone marrow. Library preparation, templating, and sequencing was performed on the fully automated Genexus Integrated Sequencer (Thermo Fisher Scientific). The sequencing data were analyzed by manual curation, default Oncomine filters and the Oncomine Reporter (Thermo Fisher Scientific).</p><p><strong>Results: </strong>Of the 600 reference pathogenic DNA variants targeted by the assay, concordance was seen in 98.3% of unfiltered variant call format files. Precision and reproducibility were 100%, and the lower limit of detection was 2% variant allele frequency for DNA. Inability to detect variants in long homopolymer regions intrinsic to the Ion Torrent chemistry led to 7 missed variants; 100% concordance was seen with reference RNA samples.</p><p><strong>Conclusions: </strong>This extensive clinical validation of the Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer with its built-in bioinformatics pipeline and Ion Torrent Oncomine Reporter shows robust performance in terms of variant calling accuracy, precision, and reproducibility, with the advantage of a rapid turnaround time of 2 days. The greatest limitation is the inability to detect variants in long homopolymer regions.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How I diagnose large granular lymphocytic leukemia. 我是如何诊断大颗粒淋巴细胞白血病的?
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1093/ajcp/aqae064
Min Shi, William George Morice

Objectives: Large granular lymphocytic leukemia (LGLL) represents a rare neoplasm of mature T cells or natural killer (NK) cells, with an indolent clinical course. Diagnosing LGLL can be challenging because of overlapping features with reactive processes and other mimickers.

Methods: By presenting 2 challenging cases, we elucidate the differentiation of LGLL from its mimics and highlight potential diagnostic pitfalls. A comprehensive review of the clinicopathologic features of LGLL was conducted.

Results: Large granular lymphocytic leukemia displays a diverse spectrum of clinical presentations, morphologies, flow cytometric immunophenotypes, and molecular profiles. These features are also encountered in reactive conditions, T-cell clones of uncertain significance, and NK cell clones of uncertain significance.

Conclusions: In light of the intricate diagnostic landscape, LGLL workup must encompass clinical, morphologic, immunophenotypic, clonal, and molecular findings. Meeting major and minor diagnostic criteria is imperative for the accurate diagnosis of LGLL.

研究目的大颗粒淋巴细胞白血病(LGLL)是一种罕见的成熟T细胞或自然杀伤细胞(NK)肿瘤,临床病程缓慢。由于大颗粒淋巴细胞白血病的特征与反应性过程和其他模仿者重叠,因此诊断大颗粒淋巴细胞白血病具有挑战性:方法:通过介绍两例具有挑战性的病例,我们阐明了 LGLL 与其模仿者的区别,并强调了潜在的诊断陷阱。我们还对 LGLL 的临床病理特征进行了全面回顾:大颗粒淋巴细胞白血病的临床表现、形态、流式细胞免疫分型和分子特征多种多样。这些特征在反应性条件、意义不明的 T 细胞克隆和意义不明的 NK 细胞克隆中也会出现:鉴于诊断情况错综复杂,LGLL 的检查必须包括临床、形态学、免疫分型、克隆和分子检查结果。符合主要和次要诊断标准是准确诊断 LGLL 的必要条件。
{"title":"How I diagnose large granular lymphocytic leukemia.","authors":"Min Shi, William George Morice","doi":"10.1093/ajcp/aqae064","DOIUrl":"https://doi.org/10.1093/ajcp/aqae064","url":null,"abstract":"<p><strong>Objectives: </strong>Large granular lymphocytic leukemia (LGLL) represents a rare neoplasm of mature T cells or natural killer (NK) cells, with an indolent clinical course. Diagnosing LGLL can be challenging because of overlapping features with reactive processes and other mimickers.</p><p><strong>Methods: </strong>By presenting 2 challenging cases, we elucidate the differentiation of LGLL from its mimics and highlight potential diagnostic pitfalls. A comprehensive review of the clinicopathologic features of LGLL was conducted.</p><p><strong>Results: </strong>Large granular lymphocytic leukemia displays a diverse spectrum of clinical presentations, morphologies, flow cytometric immunophenotypes, and molecular profiles. These features are also encountered in reactive conditions, T-cell clones of uncertain significance, and NK cell clones of uncertain significance.</p><p><strong>Conclusions: </strong>In light of the intricate diagnostic landscape, LGLL workup must encompass clinical, morphologic, immunophenotypic, clonal, and molecular findings. Meeting major and minor diagnostic criteria is imperative for the accurate diagnosis of LGLL.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement. 带有 CBFB 重排的急性髓性白血病的免疫表型和遗传特征综合分析。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-05-27 DOI: 10.1093/ajcp/aqae060
Fnu Sameeta, Sa A Wang, Zhenya Tang, Joseph D Khoury, Hong Fang, Dylan Wang, Jie Xu, Shaoying Li, Zhihong Hu, Shimin Hu, Jeffrey L Jorgensen, L Jeffrey Medeiros, Wei Wang

Objectives: We sought to characterize the immunophenotype of acute myeloid leukemia (AML) with CBFB rearrangement and correlate the results with cytogenetic and molecular data.

Methods: Sixty-one cases of AML with CBFB rearrangement were evaluated.

Results: The sample population consisted of 33 men and 28 women, with a median age of 49 years. Flow cytometry immunophenotypic analysis showed that myeloblasts were positive for CD34 and CD117 in all cases, and myeloperoxidase was positive in 52 of 55 (95%) cases. The most common abnormalities included decreased CD38 in 90%, increased CD13 in 85%, increased CD123 in 84%, and decreased HLA-DR in 84% of cases. Monocytes were increased, with a mature immunophenotype, and accounted for 23.7% of total cells. Among 60 cases with available karyotype, inv(16)(p13.1q22) was most common in 50 (83%) cases, followed by t(16;16) (p13.1;q22) in 6 (10%). Type A CBFB::MYH11 transcript was most common, detected in 84% of cases. Mutational analysis showed mutations of NRAS in 37%, FLT3 in 25%, and KIT in 24% of cases. Comparing cases with type A vs non-type A transcripts, blasts in type A cases more frequently exhibited CD64 positivity and increased CD13 levels while showing a lower frequency of CD7 and CD56 expression. Trisomy 22 and mutations in KIT, NF1, and TET2 were identified only in cases with type A transcript.

Conclusions: Myeloblasts of AML with CBFB rearrangement are positive for CD34, CD117, and myeloperoxidase. These neoplasms most frequently carry inv(16)(p13.1q22) and type A fusion transcript. NRAS mutation was the most common mutation. Some immunophenotypic and genetic correlations occurred with different types of transcripts.

目的:我们试图描述伴有CBFB重排的急性髓性白血病(AML)的免疫表型,并将结果与细胞遗传学和分子数据进行关联:我们试图描述伴有CBFB重排的急性髓性白血病(AML)的免疫表型特征,并将结果与细胞遗传学和分子数据相关联:方法:对61例CBFB重排的急性髓性白血病病例进行了评估:结果:样本人群包括 33 名男性和 28 名女性,中位年龄为 49 岁。流式细胞术免疫表型分析显示,所有病例的骨髓细胞 CD34 和 CD117 均呈阳性,55 例病例中有 52 例(95%)骨髓过氧化物酶呈阳性。最常见的异常包括 90% 的病例中 CD38 减少,85% 的病例中 CD13 增加,84% 的病例中 CD123 增加,84% 的病例中 HLA-DR 减少。单核细胞增多,免疫表型成熟,占细胞总数的 23.7%。在 60 例可提供核型的病例中,inv(16)(p13.1q22) 最常见,占 50 例(83%),其次是 t(16;16) (p13.1;q22),占 6 例(10%)。A型CBFB::MYH11转录本最常见,在84%的病例中检测到。突变分析显示,37%的病例存在NRAS突变,25%的病例存在FLT3突变,24%的病例存在KIT突变。比较A型与非A型转录本的病例,A型病例的胚泡更常表现出CD64阳性和CD13水平升高,而CD7和CD56的表达频率较低。只有在A型转录本病例中才发现了22三体综合征以及KIT、NF1和TET2突变:结论:具有 CBFB 重排的急性髓细胞性白血病骨髓母细胞的 CD34、CD117 和髓过氧化物酶均呈阳性。这些肿瘤最常携带 inv(16)(p13.1q22) 和 A 型融合转录本。NRAS突变是最常见的突变。不同类型的转录本存在一些免疫表型和遗传相关性。
{"title":"Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement.","authors":"Fnu Sameeta, Sa A Wang, Zhenya Tang, Joseph D Khoury, Hong Fang, Dylan Wang, Jie Xu, Shaoying Li, Zhihong Hu, Shimin Hu, Jeffrey L Jorgensen, L Jeffrey Medeiros, Wei Wang","doi":"10.1093/ajcp/aqae060","DOIUrl":"https://doi.org/10.1093/ajcp/aqae060","url":null,"abstract":"<p><strong>Objectives: </strong>We sought to characterize the immunophenotype of acute myeloid leukemia (AML) with CBFB rearrangement and correlate the results with cytogenetic and molecular data.</p><p><strong>Methods: </strong>Sixty-one cases of AML with CBFB rearrangement were evaluated.</p><p><strong>Results: </strong>The sample population consisted of 33 men and 28 women, with a median age of 49 years. Flow cytometry immunophenotypic analysis showed that myeloblasts were positive for CD34 and CD117 in all cases, and myeloperoxidase was positive in 52 of 55 (95%) cases. The most common abnormalities included decreased CD38 in 90%, increased CD13 in 85%, increased CD123 in 84%, and decreased HLA-DR in 84% of cases. Monocytes were increased, with a mature immunophenotype, and accounted for 23.7% of total cells. Among 60 cases with available karyotype, inv(16)(p13.1q22) was most common in 50 (83%) cases, followed by t(16;16) (p13.1;q22) in 6 (10%). Type A CBFB::MYH11 transcript was most common, detected in 84% of cases. Mutational analysis showed mutations of NRAS in 37%, FLT3 in 25%, and KIT in 24% of cases. Comparing cases with type A vs non-type A transcripts, blasts in type A cases more frequently exhibited CD64 positivity and increased CD13 levels while showing a lower frequency of CD7 and CD56 expression. Trisomy 22 and mutations in KIT, NF1, and TET2 were identified only in cases with type A transcript.</p><p><strong>Conclusions: </strong>Myeloblasts of AML with CBFB rearrangement are positive for CD34, CD117, and myeloperoxidase. These neoplasms most frequently carry inv(16)(p13.1q22) and type A fusion transcript. NRAS mutation was the most common mutation. Some immunophenotypic and genetic correlations occurred with different types of transcripts.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ChatGPT as a teaching tool: Preparing pathology residents for board examination with AI-generated digestive system pathology tests. 将 ChatGPT 作为教学工具:用人工智能生成的消化系统病理学测试为病理学住院医师考试做准备。
IF 3.5 4区 医学 Q1 Medicine Pub Date : 2024-05-25 DOI: 10.1093/ajcp/aqae062
Thiyaphat Laohawetwanit, Sompon Apornvirat, Charinee Kantasiripitak

Objectives: To evaluate the effectiveness of ChatGPT 4 in generating multiple-choice questions (MCQs) with explanations for pathology board examinations, specifically for digestive system pathology.

Methods: The customized ChatGPT 4 model was developed for MCQ and explanation generation. Expert pathologists evaluated content accuracy and relevance. These MCQs were then administered to pathology residents, followed by an analysis focusing on question difficulty, accuracy, item discrimination, and internal consistency.

Results: The customized ChatGPT 4 generated 80 MCQs covering various gastrointestinal and hepatobiliary topics. While the MCQs demonstrated moderate to high agreement in evaluation parameters such as content accuracy, clinical relevance, and overall quality, there were issues in cognitive level and distractor quality. The explanations were generally acceptable. Involving 9 residents with a median experience of 1 year, the average score was 57.4 (71.8%). Pairwise comparisons revealed a significant difference in performance between each year group (P < .01). The test analysis showed moderate difficulty, effective item discrimination (index = 0.15), and good internal consistency (Cronbach's α = 0.74).

Conclusions: ChatGPT 4 demonstrated significant potential as a supplementary educational tool in medical education, especially in generating MCQs with explanations similar to those seen in board examinations. While artificial intelligence-generated content was of high quality, it necessitated refinement and expert review.

目的评估 ChatGPT 4 在为病理学考试(特别是消化系统病理学)生成附有解释的多选题(MCQ)方面的有效性:开发了用于生成 MCQ 和解释的定制 ChatGPT 4 模型。病理专家对内容的准确性和相关性进行了评估。然后将这些 MCQ 交给病理学住院医师,然后对问题的难度、准确性、项目区分度和内部一致性进行分析:结果:定制的 ChatGPT 4 生成了 80 个 MCQ,涵盖了各种胃肠道和肝胆主题。虽然 MCQ 在内容准确性、临床相关性和整体质量等评价参数方面表现出中等至高等的一致性,但在认知水平和干扰项质量方面存在问题。解释总体上可以接受。9 名住院医师的平均年龄为 1 年,平均得分为 57.4 分(71.8%)。配对比较显示,每个年级组之间的成绩差异显著(P 结论):ChatGPT 4 作为医学教育中的辅助教学工具,尤其是在生成与医师资格考试中的解释类似的 MCQ 方面,表现出了巨大的潜力。虽然人工智能生成的内容质量很高,但仍需改进和专家审核。
{"title":"ChatGPT as a teaching tool: Preparing pathology residents for board examination with AI-generated digestive system pathology tests.","authors":"Thiyaphat Laohawetwanit, Sompon Apornvirat, Charinee Kantasiripitak","doi":"10.1093/ajcp/aqae062","DOIUrl":"https://doi.org/10.1093/ajcp/aqae062","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effectiveness of ChatGPT 4 in generating multiple-choice questions (MCQs) with explanations for pathology board examinations, specifically for digestive system pathology.</p><p><strong>Methods: </strong>The customized ChatGPT 4 model was developed for MCQ and explanation generation. Expert pathologists evaluated content accuracy and relevance. These MCQs were then administered to pathology residents, followed by an analysis focusing on question difficulty, accuracy, item discrimination, and internal consistency.</p><p><strong>Results: </strong>The customized ChatGPT 4 generated 80 MCQs covering various gastrointestinal and hepatobiliary topics. While the MCQs demonstrated moderate to high agreement in evaluation parameters such as content accuracy, clinical relevance, and overall quality, there were issues in cognitive level and distractor quality. The explanations were generally acceptable. Involving 9 residents with a median experience of 1 year, the average score was 57.4 (71.8%). Pairwise comparisons revealed a significant difference in performance between each year group (P < .01). The test analysis showed moderate difficulty, effective item discrimination (index = 0.15), and good internal consistency (Cronbach's α = 0.74).</p><p><strong>Conclusions: </strong>ChatGPT 4 demonstrated significant potential as a supplementary educational tool in medical education, especially in generating MCQs with explanations similar to those seen in board examinations. While artificial intelligence-generated content was of high quality, it necessitated refinement and expert review.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141096823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of clinical pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1